Login to Your Account



Higher Risk, Higher Reward

Algeta Opts for 50-50 Split in Bayer Deal for Alpharadin

By Nuala Moran
Staff Writer

Wednesday, April 18, 2012
LONDON – Algeta ASA decided to go for the higher-risk, but hopefully more profitable route in U.S. commercialization of Alpharadin, exercising an option last week on a 50-50 co-promotion agreement for which it is liable for half the costs.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription